The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
B‐cell Therapy for Multiple Sclerosis: Entering an era
Open accessAbstract
Monoclonal antibodies that target CD20 expressing B cells represent an important new treatment option for patients with multiple sclerosis (MS). B‐cell‐depleting therapy is highly effective against relapsing forms of the disease and is also the first treatment approach proven to protect against disability worsening in primary progressive MS. Moreover, evolving clinical experience with B‐cell therapy, combined with a more sophisticated understanding of humoral immunity in preclinical models and in patients with MS, has led to major progress in deciphering the immune pathogenesis of MS. Here, we review the nuanced roles of B cells in MS autoimmunity, the clinical data supporting use of ocrelizumab and other anti‐CD20 therapies in the treatment of MS, as well as safety and practical considerations for prescribing. Last, we summarize remaining unanswered questions regarding the proper role of anti‐CD20 therapy in MS, its limitations, and the future landscape of B‐cell‐based approaches to treatment. Ann Neurol 2018;83:13–26
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Yang, J., Jiang, Z., Fitzgerald, D. C., Ma, C., Yu, S., Li, H., Zhao, Z., Li, Y., Ciric, B., Curtis, M., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37914 · Cited by 194
RetractedStructural and functional features of central nervous system lymphatic vessels
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., Lee, K. S., et al. (2015) · Nature · doi:10.1038/nature14432 · Cited by 4,413
New Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citationOcrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021
Self-citationOcrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905 · cited 6×
“Pivotal MS Trials With Ocrelizumab Study Ocrelizumab vs Placebo in Primary Progressive Multiple Sclerosisa Ocrelizumab vs Interferon Beta-1a in Relapsing Multiple Sclerosisb Design Phase 3, randomized 2:1 OCR vs placebo Tandem (2) phase 3 trials, randomized 1:1 OCR vs IFNb-1a No. of patients 732 (488 OCR; 244 placebo)…”
BackgroundInfluentialSelf-citationB cells regulate autoimmunity by provision of IL-10
Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D., & Anderton, S. M. (2002) · Nature Immunology · doi:10.1038/ni833 · Cited by 1,647
von Büdingen, H.-C., Palanichamy, A., Lehmann-Horn, K., Michel, B. A., & Zamvil, S. S. (2015) · European Neurology · doi:10.1159/000377675 · Cited by 1,463
Magliozzi, R., Howell, O., Vora, A., Serafini, B., Nicholas, R., Puopolo, M., Reynolds, R., & Aloisi, F. (2006) · Brain · doi:10.1093/brain/awm038 · Cited by 1,443
Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion
Barnett, M. H., & Prineas, J. W. (2004) · Annals of Neurology · doi:10.1002/ana.20016 · Cited by 1,185
Fate mapping of IL-17-producing T cells in inflammatory responses
Hirota, K., Duarte, J. H., Veldhoen, M., Hornsby, E., Li, Y., Cua, D. J., Ahlfors, H., Wilhelm, C., Tolaini, M., Menzel, U., et al. (2011) · Nature Immunology · doi:10.1038/ni.1993 · Cited by 1,176
Inflammatory cortical demyelination in early multiple sclerosis.
Lucchinetti, C. F., Popescu, B. F. G., Bunyan, R. F., Moll, N. M., Roemer, S. F., Lassmann, H., Brück, W., Parisi, J. E., Scheithauer, B. W., Giannini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100648 · Cited by 1,103
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
Guillevin, L., Pagnoux, C., Karras, A., Khouatra, C., Aumaître, O., Cohen, P., Maurier, F., Decaux, O., Ninet, J., Gobert, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404231 · Cited by 1,090
Shen, P., Roch, T., Lampropoulou, V., O’Connor, R. A., Stervbo, U., Hilgenberg, E., Ries, S., Dang, V. D., Jaimes, Y., Daridon, C., et al. (2014) · Nature · doi:10.1038/nature12979 · Cited by 1,048
Hawker, K., O'Connor, P., Freedman, M. S., Calabresi, P. A., Antel, J., Simon, J., Hauser, S., Waubant, E., Vollmer, T., Panitch, H., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21867 · Cited by 934
Self-citationRegulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression
Matsushita, T., Yanaba, K., Bouaziz, J.-D., Fujimoto, M., & Tedder, T. F. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36030 · Cited by 913
The who, how and where of antigen presentation to B cells
Batista, F. D., & Harwood, N. E. (2009) · Nature Reviews Immunology · doi:10.1038/nri2454 · Cited by 775
Kappos, L., Li, D., Calabresi, P. A., O'Connor, P., Bar-Or, A., Barkhof, F., Yin, M., Leppert, D., Glanzman, R., Tinbergen, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61649-8 · Cited by 743
Self-citationRituximab for IgG4-related disease: a prospective, open-label trial
Carruthers, M. N., Topazian, M. D., Khosroshahi, A., Witzig, T. E., Wallace, Z. S., Hart, P. A., Deshpande, V., Smyrk, T. C., Chari, S., & Stone, J. H. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206605 · Cited by 726
OBSERVATIONS ON ATTEMPTS TO PRODUCE ACUTE DISSEMINATED ENCEPHALOMYELITIS IN MONKEYS
Rivers, T. M., Sprunt, D. H., & Berry, G. P. (1933) · Journal of Experimental Medicine · doi:10.1084/jem.58.1.39 · Cited by 643
Teeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Teeling, J. L., Mackus, W. J. M., Wiegman, L. J. J. M., van den Brakel, J. H. N., Beers, S. A., French, R. R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J. W., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.362 · Cited by 609
Cytokine-producing B lymphocytes-key regulators of immunity
Lund, F. E. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.03.003 · Cited by 556
Abnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS?
Bar‐Or, A., Fawaz, L., Fan, B., Darlington, P. J., Rieger, A., Ghorayeb, C., Calabresi, P. A., Waubant, E., Hauser, S. L., Zhang, J., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21939 · Cited by 521
Self-citationPlasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations
Wallace, Z. S., Mattoo, H., Carruthers, M., Mahajan, V. S., Della Torre, E., Lee, H., Kulikova, M., Deshpande, V., Pillai, S., & Stone, J. H. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205233 · Cited by 494
Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
Cross, A. H., Stark, J. L., Lauber, J., Ramsbottom, M. J., & Lyons, J.-A. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.06.029 · Cited by 454
Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy
Li, R., Rezk, A., Miyazaki, Y., Hilgenberg, E., Touil, H., Shen, P., Moore, C. S., Michel, L., Althekair, F., Rajasekharan, S., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab4176 · Cited by 453
B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes
Stern, J. N. H., Yaari, G., Vander Heiden, J. A., Church, G., Donahue, W. F., Hintzen, R. Q., Huttner, A. J., Laman, J. D., Nagra, R. M., Nylander, A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008879 · Cited by 441
Long‐term evolution of multiple sclerosis disability in the treatment era
University of California, S. F. M. T., Cree, B. A. C., Gourraud, P., Oksenberg, J. R., Bevan, C., Crabtree‐Hartman, E., Gelfand, J. M., Goodin, D. S., Graves, J., Green, A. J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24747 · Cited by 440
Self-citationENCEPHALOMYELITIS ACCOMPANIED BY MYELIN DESTRUCTION EXPERIMENTALLY PRODUCED IN MONKEYS
Rivers, T. M., & Schwentker, F. F. (1935) · Journal of Experimental Medicine · doi:10.1084/jem.61.5.689 · Cited by 435
Molnarfi, N., Schulze-Topphoff, U., Weber, M. S., Patarroyo, J. C., Prod’homme, T., Varrin-Doyer, M., Shetty, A., Linington, C., Slavin, A. J., Hidalgo, J., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130699 · Cited by 418
Cepok, S., Rosche, B., Grummel, V., Vogel, F., Zhou, D., Sayn, J., Sommer, N., Hartung, H.-P., & Hemmer, B. (2005) · Brain · doi:10.1093/brain/awh486 · Cited by 367
Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
Salzer, J., Svenningsson, R., Alping, P., Novakova, L., Björck, A., Fink, K., Islam-Jakobsson, P., Malmeström, C., Axelsson, M., Vågberg, M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003331 · Cited by 354
Autoantigen discovery with a synthetic human peptidome
Larman, H. B., Zhao, Z., Laserson, U., Li, M. Z., Ciccia, A., Gakidis, M. A. M., Church, G. M., Kesari, S., LeProust, E. M., Solimini, N. L., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1856 · Cited by 348
Kappos, L., Hartung, H.-P., Freedman, M. S., Boyko, A., Radü, E. W., Mikol, D. D., Lamarine, M., Hyvert, Y., Freudensprung, U., Plitz, T., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70028-6 · Cited by 338
Roll, P., Palanichamy, A., Kneitz, C., Dorner, T., & Tony, H. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22019 · Cited by 321
Weber, M. S., Prod'homme, T., Patarroyo, J. C., Molnarfi, N., Karnezis, T., Lehmann‐Horn, K., Danilenko, D. M., Eastham‐Anderson, J., Slavin, A. J., Linington, C., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22081 · Cited by 318
B cells as antigen presenting cells
Rodríguez-Pinto, D. (2005) · Cellular Immunology · doi:10.1016/j.cellimm.2006.02.005 · Cited by 297
Lyons, J.-A., San, M., Happ, M. P., & Cross, A. H. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199911)29:11<3432::aid-immu3432>3.0.co;2-2 · Cited by 292
Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients
Palanichamy, A., Jahn, S., Nickles, D., Derstine, M., Abounasr, A., Hauser, S. L., Baranzini, S. E., Leppert, D., & von Büdingen, H.-C. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400118 · Cited by 289
Self-citationSafety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study
Sorensen, P. S., Lisby, S., Grove, R., Derosier, F., Shackelford, S., Havrdova, E., Drulovic, J., & Filippi, M. (2014) · Neurology · doi:10.1212/wnl.0000000000000125 · Cited by 278
Rituximab treatment of myasthenia gravis: A systematic review: Rituximab in Myasthenia Gravis
Tandan, R., Hehir, M. K., Waheed, W., & Howard, D. B. (2017) · Muscle & Nerve · doi:10.1002/mus.25597 · Cited by 275
Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple Sclerosis
Piccio, L., Naismith, R. T., Trinkaus, K., Klein, R. S., Parks, B. J., Lyons, J. A., & Cross, A. H. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.99 · Cited by 274
T cell responses in the central nervous system
Korn, T., & Kallies, A. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.144 · Cited by 268
Pathology of Multiple Sclerosis: Where Do We Stand?
Popescu, B. F. G., Pirko, I., & Lucchinetti, C. F. (2013) · Continuum · doi:10.1212/01.con.0000433291.23091.65 · Cited by 261
Kamburova, E. G., Koenen, H. J. P. M., Borgman, K. J. E., ten Berge, I. J., Joosten, I., & Hilbrands, L. B. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12220 · Cited by 257
MHC haplotype-dependent regulation of MOG-induced EAE in rats.
Weissert, R., Wallström, E., Storch, M. K., Stefferl, A., Lorentzen, J., Lassmann, H., Linington, C., & Olsson, T. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3022 · Cited by 256
Vallerskog, T., Gunnarsson, I., Widhe, M., Risselada, A., Klareskog, L., van Vollenhoven, R., Malmström, V., & Trollmo, C. (2007) · Clinical Immunology · doi:10.1016/j.clim.2006.08.016 · Cited by 240
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
Alping, P., Frisell, T., Novakova, L., Islam‐Jakobsson, P., Salzer, J., Björck, A., Axelsson, M., Malmeström, C., Fink, K., Lycke, J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24651 · Cited by 230
Palanichamy, A., Apeltsin, L., Kuo, T. C., Sirota, M., Wang, S., Pitts, S. J., Sundar, P. D., Telman, D., Zhao, L. Z., Derstine, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008930 · Cited by 225
Self-citationWang, Y., Godec, J., Ben-Aissa, K., Cui, K., Zhao, K., Pucsek, A. B., Lee, Y. K., Weaver, C. T., Yagi, R., & Lazarevic, V. (2014) · Immunity · doi:10.1016/j.immuni.2014.01.002 · Cited by 207
B cells as therapeutic targets in autoimmune neurological disorders
Dalakas, M. C. (2008) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0901 · Cited by 202
Rituximab monotherapy for patients with recurrent primary CNS lymphoma
Batchelor, T. T., Grossman, S. A., Mikkelsen, T., Ye, X., Desideri, S., & Lesser, G. J. (2011) · Neurology · doi:10.1212/wnl.0b013e31820f2d94 · Cited by 197
Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
Hauser, S. L., Kappos, L., Montalban, X., Craveiro, L., Chognot, C., Hughes, R., Koendgen, H., Pasquarelli, N., Pradhan, A., Prajapati, K., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012700 · Cited by 197
Self-citationThe effect of rituximab on vaccine responses in patients with immune thrombocytopenia
Nazi, I., Kelton, J. G., Larché, M., Snider, D. P., Heddle, N. M., Crowther, M. A., Cook, R. J., Tinmouth, A. T., Mangel, J., & Arnold, D. M. (2013) · Blood · doi:10.1182/blood-2013-04-494096 · Cited by 192
Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins
Brändle, S. M., Obermeier, B., Senel, M., Bruder, J., Mentele, R., Khademi, M., Olsson, T., Tumani, H., Kristoferitsch, W., Lottspeich, F., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522730113 · Cited by 190
Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid
Owens, G. P., Bennett, J. L., Lassmann, H., O'Connor, K. C., Ritchie, A. M., Shearer, A., Lam, C., Yu, X., Birlea, M., DuPree, C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21641 · Cited by 188
Walsh, M. J., & Tourtellotte, W. W. (1986) · The Journal of experimental medicine · doi:10.1084/jem.163.1.41 · Cited by 168
Specific peripheral B cell tolerance defects in patients with multiple sclerosis
Kinnunen, T., Chamberlain, N., Morbach, H., Cantaert, T., Lynch, M., Preston-Hurlburt, P., Herold, K. C., Hafler, D. A., O’Connor, K. C., & Meffre, E. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68775 · Cited by 164
Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS
Kowarik, M. C., Pellkofer, H. L., Cepok, S., Korn, T., Kümpfel, T., Buck, D., Hohlfeld, R., Berthele, A., & Hemmer, B. (2011) · Neurology · doi:10.1212/wnl.0b013e3182143564 · Cited by 159
Agius, M. A., Kłodowska-Duda, G. A., Maciejowski, M., Potemkowski, A., Li, J., Patra, K., Wesley, J. B., Madani, S., Barron, G., Katz, E., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517740641 · Cited by 150
Obermeier, B., Lovato, L., Mentele, R., Brück, W., Forné, I., Imhof, A., Lottspeich, F., Turk, K. W., Willis, S. N., Wekerle, H., et al. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.01.010 · Cited by 139
Larman, H. B., Laserson, U., Querol, L., Verhaeghen, K., Solimini, N. L., Xu, G. J., Klarenbeek, P. L., Church, G. M., Hafler, D. A., Plenge, R. M., et al. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.01.013 · Cited by 126
Valgardsdottir, R., Cattaneo, I., Klein, C., Introna, M., Figliuzzi, M., & Golay, J. (2017) · Blood · doi:10.1182/blood-2016-08-735605 · Cited by 124
A new primate model for multiple sclerosis in the common marmoset
Hart, B. A. ‘., van Meurs, M., Brok, H., Massacesi, L., Bauer, J., Boon, L., Bontrop, R. E., & Laman, J. D. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01627-3 · Cited by 112
Rudick, R. A., Cookfair, D. L., Simonian, N. A., Ransohoff, R. M., Richert, J. R., Jacobs, L. D., Herndon, R. M., Salazar, A. Μ., Fischer, J. S., Granger, C. V., et al. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00174-x · Cited by 104
The Charcot Lecture | Beating MS: A story of B cells, with twists and turns
Hauser, S. L. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514561911 · Cited by 101
Self-citationvon Büdingen, H. ‐., Harrer, M. D., Kuenzle, S., Meier, M., & Goebels, N. (2008) · European Journal of Immunology · doi:10.1002/eji.200737784 · Cited by 98
Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients
Eggers, E. L., Michel, B. A., Wu, H., Wang, S.-Z., Bevan, C. J., Abounasr, A., Pierson, N. S., Bischof, A., Kazer, M., Leitner, E., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92724 · Cited by 93 · cited 1×
“Plasmablasts appear to be an important source of secreted immunoglobulin (Ig) in the CSF,(29,30) as well as a correlate of disease severity(28) and gadoliniumenhancing lesions.(28,31) Sequencing studies of B-cell receptor (BCR) genes from CSF plasmablasts and B cells have revealed that: (1) CSF plasmablasts are derive…”
BackgroundSelf-citationIn multiple sclerosis, oligoclonal bands connect to peripheral B‐cell responses
Bankoti, J., Apeltsin, L., Hauser, S. L., Allen, S., Albertolle, M. E., Witkowska, H. E., & von Büdingen, H. ‐. (2013) · Annals of Neurology · doi:10.1002/ana.24088 · Cited by 92
Self-citationB-Cell Therapies in Multiple SclerosisPreprint
Sabatino, J. J., Zamvil, S. S., & Hauser, S. L. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a032037 · Cited by 88
Self-citationAttachment of myelin to coated pits on macrophages in experimental allergic encephalomyelitis
Epstein, L. G., Prineas, J. W., & Raine, C. S. (1983) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(83)90167-3 · Cited by 83
Ray, A., Mann, M. K., Basu, S., & Dittel, B. N. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.10.037 · Cited by 81
Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program
Emery, P., Rigby, W. F. C., Tak, P. P., Dörner, T., Olech, E., Martín, C., Millar, L., Travers, H., & Fisheleva, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087379 · Cited by 81
Development of Novel Tetravalent Anti-CD20 Antibodies with Potent Antitumor Activity
Li, B., Shi, S., Qian, W., Zhao, L., Zhang, D., Hou, S., Zheng, L., Dai, J., Zhao, J., Wang, H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6663 · Cited by 74
Holley, J. E., Bremer, E., Kendall, A. C., de Bruyn, M., Helfrich, W., Tarr, J. M., Newcombe, J., Gutowski, N. J., & Eggleton, P. (2014) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2014.06.001 · Cited by 71
Multiple sclerosis de novo CNS IgG synthesis
Tourtellotte, W. W., Baumhefner, R. W., Potvin, A. R., Boce, I., Potvin, J. H., Mendez, M. F., & Syndulko, K. (1980) · Neurology · doi:10.1212/wnl.30.11.1155 · Cited by 70
Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity
Longbrake, E. E., & Cross, A. H. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3977 · Cited by 64
Sharman, J. P., Farber, C. M., Mahadevan, D., Schreeder, M. T., Brooks, H. D., Kolibaba, K. S., Fanning, S. R., Klein, L. M., Greenwald, D. R., Sportelli, P., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14447 · Cited by 64
Vaccines and Disease-Modifying Antirheumatic Drugs
Friedman, M., & Winthrop, K. L. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2016.09.003 · Cited by 60
Petereit, H.-F., Moeller‐Hartmann, W., Reske, D., & RUBBERT, A. (2007) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00958.x · Cited by 59
Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence
Etemadifar, M., Salari, M., Mirmosayyeb, O., Serati, M., Nikkhah, R., Askari, M., & Fayyazi, E. (2017) · Journal of Research in Medical Sciences · doi:10.4103/1735-1995.200275 · Cited by 58
Monoclonal antibody as therapy for malignant lymphomas
Coiffier, B. (2006) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2005.12.006 · Cited by 57
von Büdingen, H. ‐., Gulati, M., Kuenzle, S., Fischer, K., Rupprecht, T. A., & Goebels, N. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.10.005 · Cited by 54
Safety issues of biologics in pregnant patients with rheumatic diseases
Østensen, M. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12456 · Cited by 53
Good and bad memories following rituximab therapy
Clair, E. W. S. (2009) · Arthritis & Rheumatism · doi:10.1002/art.25039 · Cited by 51
Increased ex vivo antigen presentation profile of B cells in multiple sclerosis
Mathias, A., Perriard, G., Canales, M., Soneson, C., Delorenzi, M., Schluep, M., & Pasquier, R. D. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516664210 · Cited by 50
Giacomini, E., Rizzo, F., Etna, M. P., Cruciani, M., Mechelli, R., Buscarinu, M. C., Pica, F., D’Agostini, C., Salvetti, M., Coccia, E. M., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517695892 · Cited by 42
Allergic Encephalomyelitis in Common Marmosets: Pathogenesis of a Multiple Sclerosis-like Lesion
Genain, C. P., & Hauser, S. L. (1996) · Methods · doi:10.1006/meth.1996.0120 · Cited by 41
Self-citationEffects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica
Graves, J., Vinayagasundaram, U., Mowry, E. M., Matthews, I. R., Marino, J. A., Cheng, J., & Waubant, E. L. (2013) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2013.10.003 · Cited by 40
Axelsson, M., Mattsson, N., Malmeström, C., Zetterberg, H., & Lycke, J. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.09.003 · Cited by 39
Yu, X., Burgoon, M. P., Green, M., Barmina, O. Y., Dennison, K., Pointon, T., Davis, M., & Gilden, D. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.10.009 · Cited by 29
Experimental allergic optic neuritis in guinea pigs: preliminary report.
Rao, N. A., Tso, M. O. M., & Zimmerman, E. L. (1977) · PubMed · Cited by 26
Confavreux, C., Chapuis‐Cellier, C., Arnaud, P., Robert, O., Aimard, G., & Devic, M. (1986) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.49.11.1308 · Cited by 26
Onset of secondary progressive MS after long‐term rituximab therapy – a case report
von Büdingen, H. ‐., Bischof, A., Eggers, E. L., Wang, S., Bevan, C. J., Cree, B., Henry, R. G., & Hauser, S. L. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.377 · Cited by 25
Self-citationRituximab therapy in pemphigus and other autoantibody-mediated diseases
Ran, N. A., & Payne, A. (2017) · F1000Research · doi:10.12688/f1000research.9476.1 · Cited by 23
Dock, J., Hultin, L. E., Hultin, P. M., Elliot, J. E., Yang, O. O., Anton, P. A., Jamieson, B. D., & Effros, R. B. (2017) · Journal of Immunological Methods · doi:10.1016/j.jim.2017.03.014 · Cited by 14
Persistent B lymphocytes in multiple sclerosis plaques after rituximab treatment (P5.341)
esfandi, S., Salimian, S., Corboy, J. R., & Álvarez, E. (2017) · Neurology · doi:10.1212/wnl.88.16_supplement.p5.341 · Cited by 8
Immunogenicity of biologic agents: A new concern for the practicing rheumatologist?
Haraoui, B. P., Pelletier, J., & Martel‐Pelletier, J. (2007) · Current Rheumatology Reports · doi:10.1007/s11926-007-0042-x · Cited by 6
Clonal B cell persistence in multiple sclerosis: A longitudinal immune repertoire study (P1.383)
Greenfield, A. L., Eggers, E. L., Wu, H., Laurent, S. A., Michel, B., Harkin, W. E., Pierson, N. S., Cree, B., Wilson, M. R., Hauser, S. L., et al. (2017) · Neurology · doi:10.1212/wnl.88.16_supplement.p1.383 · Cited by 1
Self-citation
Cited by
Dobson, R., & Giovannoni, G. (2019) · European Journal of Neurology · doi:10.1111/ene.13819 · Cited by 2,148
Treatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969
Self-citationMultiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy
Muzio, L., Viotti, A., & Martino, G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.742065 · Cited by 581
Tahara, M., Oeda, T., Okada, K., Kiriyama, T., Ochi, K., Maruyama, H., Fukaura, H., Nomura, K., Shimizu, Y., Mori, M., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30066-1 · Cited by 378
Metadata
- Authors
- Greenfield, A. L., & Hauser, S. L.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2018-01
- Volume
- 83
- Issue
- 1
- Pages
- 13-26
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2774037113
- Cited by
- 265
- References
- 100
- FWCI
- 14.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.